Table 5.
Specific miRNA | DNA repair gene targets | Cancers affected (frequency if measured) | References indicating epigenetic control of miRNA | References indicating target gene(s) of miRNAs | References indicating cancer type(s) affected |
miR-103 miR-107 | RAD51, RAD51D | Osteosarcoma, lung, endometrial, stomach | [100] | [101] | [101] |
miR-34c | UNG | Gastric (70%) field defect gastric (27%) colon (98%) field defect colon (60%) chronic lymphocytic leukemia (18%) small-cell lung cancer (67%) NSCLC (26%) | [102,104] | [103] | [102,105,106] |
miR-31 | PARP1 MLH1 SMUG1 MMS19 | Esophagus (47%) colon | [72] | [21] | [71,107,108] |
miR-124 | KU70 | Colon | [109] | [110] | [109] |
miR-155 | RAD51 MLH1 MSH2 MSH6 | Breast Colon | [90,111] | [23,112] | [23,90] |
let-7a repression increases HMGA2; HMGA2 alters chromatin architecture of and represses ERCC1) | ERCC1 | (Colon) Anaplastic astrocytoma | [90] | [92,113] | [113] |
Let-7b repression increases HMGA1; HMGA1 targets P53 | P53 | Prostate Colon | [90] | [114,115] | [114,115] |
miR-182 | BRCA1 NBN RAD17 | Breast Colon | [116] | [117,118] | [107,117,119] |